Models:
Joseph Gordon
joseph-gordon/
ClinicalTrialsElig
0
Downloads: 1
[c09aa8]: / clusters / final9knumclusters / clust_1715.txt

Download this file

142 lines (141 with data), 9.1 kB 

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)

Patients with an active, bleeding diathesis

Patients with a history of bleeding diathesis are ineligible

History of bleeding diathesis or clinically significant bleeding within 14 days prior to randomization.

History of hemolytic anemia or bleeding diathesis

Patients with an active, bleeding diathesis

Known hemorrhagic diathesis or active bleeding disorder

Subjects may not have a history of bleeding diathesis or abnormal sensitivity to ionizing radiation

Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)

Recent or active bleeding diathesis or arterial vascular event within 4 weeks

Patients with an active bleeding diathesis

If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis

Requires therapeutic anticoagulation or has known active bleeding diathesis

Active uncontrolled bleeding or a known bleeding diathesis

Contraindication for ibrutinib use because of a bleeding diathesis.

Evidence of a bleeding diathesis.

History of bleeding diathesis

Active uncontrolled bleeding or a known bleeding diathesis

Any evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will be excluded)

Evidence of active bleeding or bleeding diathesis

Known history of bleeding diathesis

Evidence or history of bleeding diathesis

Patients with an active bleeding diathesis

Patients with an active bleeding diathesis

Patient on anticoagulation or with bleeding diathesis due to risk of hematomas at injection site

Patients with evidence of bleeding diathesis are not eligible

For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy which cannot be interrupted for biopsy

Any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis

PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery

Evidence or history of bleeding diathesis

Must not have any evidence of bleeding diathesis or active gastrointestinal bleeding

Patients must not have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis

History of bleeding disorder or diathesis

Presence of bleeding diathesis

Evidence of active bleeding or bleeding diathesis

No active uncontrolled bleeding/bleeding diathesis

Active bleeding diathesis or history of major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within the past 6 months

Evidence of active bleeding or bleeding diathesis

Evidence of uncontrollable bleeding diathesis

Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery

Evidence of active bleeding or bleeding diathesis

Patients with an active bleeding diathesis

Bleeding diathesis, not correctable by usual forms of therapy

Bleeding diathesis, not correctable by usual forms of therapy

Active uncontrolled bleeding or a known bleeding diathesis

Haemorrhagic diathesis (i.e. haemophilia)

If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis

Active uncontrolled bleeding or a known bleeding diathesis

Patients with an active, bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Subjects with known bleeding diathesis will be excluded from the study.

Patients with history of bleeding diathesis are ineligible

Subjects with history of bleeding diathesis

Patients with evidence of active bleeding or bleeding diathesis will be excluded (patients with excess of 2.5 mL of hemoptysis are not eligible)

Evidence of bleeding diathesis

Patients with evidence of active bleeding diathesis

Patients with an active, bleeding diathesis

Patients with an active, bleeding diathesis

Patients with an active, bleeding diathesis

Patients with an active, bleeding diathesis

Known hemorrhagic diathesis or active bleeding disorder

Active bleeding diathesis or history of any major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment

History of bleeding diathesis.

Known history of a bleeding diathesis.

Evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Evidence of bleeding diathesis

History of congenital bleeding diathesis

Active bleeding diathesis

Patients with history of bleeding diathesis

History of hemolytic anemia or bleeding diathesis

In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections

Evidence of history of bleeding diathesis.

Active bleeding diathesis

Significant history of bleeding events or pre-existing bleeding diathesis =< 6 months of randomization (unless the source of bleeding has been resected)

Patients with active bleeding diathesis

Patients with evidence or history of any bleeding diathesis, irrespective of severity

Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding

Patients with evidence of a bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Any active uncontrolled bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

History of bleeding diathesis

Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding

Evidence of active bleeding or bleeding diathesis

History of bleeding diathesis or extensive bleeding requiring blood transfusion within 14 days of enrollment

Patient must not have evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Patients with an active, bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Significant history of bleeding events or pre-existing bleeding diathesis, within 6 months of randomization (unless the source of bleeding has been resected)

Evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis

EXPANSION COHORT ONLY: Evidence of active bleeding or bleeding diathesis

Known bleeding diathesis

Patients must not have any evidence of bleeding diathesis

Patients taking anticoagulants or with a history of a bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Evidence of active bleeding or bleeding diathesis; any medical condition requiring systemic anticoagulation (including anti-platelet agents)

Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.

Evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement

Evidence of active bleeding or bleeding diathesis.

Patients with an active, bleeding diathesis

Known bleeding diathesis or hemophilia

Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia (HHT).

Active, bleeding diathesis.

Known bleeding diathesis.

For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy.

No history of bleeding diathesis.

Patients with an active, bleeding diathesis

History of bleeding diathesis

Evidence of active bleeding or bleeding diathesis.

No bleeding diathesis

Patients must not have any evidence of bleeding diathesis or signs of active bleeding

History of bleeding diathesis

Known bleeding diathesis

Patients with evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement

Patients with an active, bleeding diathesis

Evidence of active bleeding or bleeding diathesis

Patients with an active, bleeding diathesis

Patients with an active, bleeding diathesis

Bleeding diathesis, resulting in symptomatic bleeding.

Evidence of active bleeding or bleeding diathesis

No known bleeding diathesis

Known bleeding or thrombotic diathesis

Bleeding diathesis or inability to hold anticoagulation for surgery

Has known bleeding diathesis that would be a safety risk;

Active bleeding diathesis

Non-correctable bleeding diathesis

Familial bleeding diathesis

Known bleeding diathesis

History of a bleeding diathesis or current anticoagulant therapy

Bleeding diathesis

active, bleeding diathesis;

Patients with or with a history of uncontrolled bleeding diathesis

No history of bleeding diathesis

Patient must not have evidence of active bleeding or bleeding diathesis

Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.

Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.